Daiichi Sankyo
![Daiichi, AZ grow ADC portfolios post Enhertu | Pharmtales](https://pharmtales.com/wp-content/uploads/2023/10/Daiichi-and-AstraZeneca-expand-ADC-pipelines-after-Enhertu-triumph.jpg)
Daiichi and AstraZeneca expand ADC pipelines after Enhertu triumph
At the European Society for Medical Oncology (ESMO) Congress, Daiichi Sankyo made a significant impact by striking a $4 billion ...
![Dato-DXd’s Mixed Results in Lung Cancer Trial (ESMO 2023)](https://pharmtales.com/wp-content/uploads/2023/10/Dato-DXd-Shows-Efficacy-in-Lung-Cancer-But-Safety-Issues-Remain-ESMO-2023.jpg)
Dato-DXd Shows Efficacy in Lung Cancer, But Safety Issues Remain (ESMO 2023)
ESMO 2023: LBA12 During the Presidential Symposium at the ESMO Congress 2023 in Madrid, a study revealed that datopotamab deruxtecan, ...
![Merck-Daiichi $22B deal for cancer ADCs](https://pharmtales.com/wp-content/uploads/2023/10/Merck-and-Daiichi-join-forces-to-develop-novel-cancer-drugs-in-22B-deal.jpg)
Merck and Daiichi join forces to develop novel cancer drugs in $22B deal
In a strategic move, Merck & Co. has solidified its position in the thriving field of antibody-drug conjugates (ADCs) through ...
![NICE rejects Enhertu for HER2-low breast cancer over cost concerns](https://pharmtales.com/wp-content/uploads/2023/09/NICE-rejects-Enhertu-for-HER2-low-breast-cancer-over-cost-concerns.jpg)
NICE rejects Enhertu for HER2-low breast cancer over cost concerns
The remarkable efficacy data that initially earned AstraZeneca and Daiichi Sankyo’s Enhertu a standing ovation at the ASCO meeting last ...
![dato-dxd breast cancer trial results, astrazeneca daiichi breast cancer adc, dato-dxd vs trodelvy breast cancer, dato-dxd fda approval status, dato-dxd progression-free survival breast cancer, dato-dxd safety and efficacy breast cancer, dato-dxd her2-low breast cancer](https://pharmtales.com/wp-content/uploads/2023/09/AstraZeneca-and-Daiichi-Reach-Key-Milestone-in-Breast-Cancer-ADC-Trial-Paving-Way-to-Challenge-Gilead.jpg)
AstraZeneca and Daiichi Reach Key Milestone in Breast Cancer ADC Trial, Paving Way to Challenge Gilead
AstraZeneca and Daiichi Sankyo are making a strategic move to challenge Gilead Sciences’ position in the breast cancer arena. They ...
![CHMP opinion, EMA approval, Daiichi Sankyo, Enhertu, Non-Small Cell Lung Cancer, HER2 Mutant NSCLC, DESTINY-Lung02 trial](https://pharmtales.com/wp-content/uploads/2023/09/Enhertu-a-Breakthrough-Therapy-for-HER2-Mutant-NSCLC-Gets-EU-Nod.jpg)
Enhertu, a Breakthrough Therapy for HER2 Mutant NSCLC, Gets EU Nod
Enhertu (trastuzumab deruxtecan) has received a positive recommendation for approval in the European Union (EU) as a standalone treatment for ...
![Quizartinib, CHMP opinion, FLT3-ITD Positive AML, EMA approval, acute myeloid leukemia, Daiichi Sankyo](https://pharmtales.com/wp-content/uploads/2023/09/Quizartinib-Gets-Green-Light-in-EU-for-Treating-Acute-Myeloid-Leukemia.jpg)
Quizartinib Gets Green Light in EU for Treating Acute Myeloid Leukemia
Daiichi Sankyo has received a positive recommendation for the approval of quizartinib in the European Union (EU). This recommendation is ...
![New drug Enhertu shows promise for HER2-mutant lung cancer patients (IASLC WCLC 2023 Conference)](https://pharmtales.com/wp-content/uploads/2023/09/New-drug-Enhertu-shows-promise-for-HER2-mutant-lung-cancer-patients.jpg)
New drug Enhertu shows promise for HER2-mutant lung cancer patients (IASLC WCLC 2023 Conference)
The International Association for the Study of Lung Cancer (IASLC) presented pivotal results from the DESTINY-Lung02 Phase II trial at ...
![Enhertu, AstraZeneca, Breakthrough Therapy Designations, HER2-positive cancers, Daiichi Sankyo, antibody drug conjugate, Trastuzumab Deruxtecan](https://pharmtales.com/wp-content/uploads/2023/09/FDA-grants-breakthrough-status-to-T-DXd-for-two-HER2-positive-cancers.jpg)
FDA grants breakthrough status to T-DXd for two HER2-positive cancers
Daiichi Sankyo and AstraZeneca have garnered FDA Breakthrough Therapy Designations (BTDs) for their Enhertu (T-DXd) therapy to treat two distinct ...
![Japan Invests $115M in Arcturus’ mRNA Manufacturing Joint Venture](https://pharmtales.com/wp-content/uploads/2023/08/Japanese-Government-Backs-Arcalis-with-115-Million-Grants-for-mRNA-Vaccine-Production.jpg)
Japanese Government Backs Arcalis with $115 Million Grants for mRNA Vaccine Production
Following Daiichi Sankyo’s recent accomplishment of securing Japan’s first mRNA vaccine approval, a potential competitor has emerged backed by significant ...
![How Daiichi Sankyo Will Rule the Antibody-Drug Conjugates Market by 2029](https://pharmtales.com/wp-content/uploads/2023/08/Daiichi-Sankyo-to-Dominate-Antibody-Drug-Conjugates-Market-by-2029.jpg)
Daiichi Sankyo to Dominate Antibody-Drug Conjugates Market by 2029
Daiichi has successfully established ADCs (Antibody-Drug Conjugates) as a significant therapeutic approach, overcoming previous years of underwhelming results. Even though ...
![Enhertu Boosts Survival in HER2+ Solid Tumors](https://pharmtales.com/wp-content/uploads/2023/07/Enhertu-increases-survival-in-solid-tumors-with-HER2.jpg)
Enhertu increases survival in solid tumors with HER2+
AstraZeneca and Daiichi Sankyo have received a boost in their efforts to gain approval for Enhertu as a therapy for ...
![Kite Successfully Transfers Marketing Authorization for Yescarta CAR T-cell Therapy in Japan](https://pharmtales.com/wp-content/uploads/2023/06/Kite-Successfully-Transfers-Marketing-Authorization-for-Yescarta-CAR-T-cell-Therapy-in-Japan.jpg)
Kite Successfully Transfers Marketing Authorization for Yescarta CAR T-cell Therapy in Japan
Source – Gilead Sciences According to Kite Pharma on June 22, 2023, the marketing authorization for Yescarta, a chimeric antigen ...